Overview

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2017-11-17

Target enrollment:

Participant gender:

Summary

This randomized phase II trial studies how well pemetrexed disodium with or without erlotinib hydrochloride works in treating patients with stage IIIB-IV or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pemetrexed disodium is more effective with or without erlotinib hydrochloride in treating non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Albert Einstein College of Medicine
Montefiore Medical Center

Collaborators:

Eli Lilly and Company
National Cancer Institute (NCI)
OSI Pharmaceuticals

Treatments:

Erlotinib Hydrochloride
Pemetrexed